Risk stratification based on size of equivocal PI-RADS lesions may safely reduce the number of MRI-targeted biopsies ‌ D.F. Osses, C. Arsov, L. Schimmöller, P. Albers, M.J. Roobol

Ստացեք ամբողջական տեքստը

Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate ‌ M. Boschheidgen, L. Schimmöller, S. Doerfler, R. Al-Monajjed, J. Morawitz, F. Ziayee, D. Mally, M. Quentin, C. Arsov, P. Albers, G. Antoch, T. Ullrich

Ստացեք ամբողջական տեքստը

Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy ‌ M Klingebiel, C Arsov, T Ullrich, M Quentin, R Al-Monajjed, D Mally, LM Sawicki, A Hiester, I Esposito, P Albers, G Antoch, L Schimmöller

Ստացեք ամբողջական տեքստը

Effect of sexual behavior on prostate-specific antigen levels in middle-aged men screened for prostate cancer: Results from the PROBASE trial ‌ V.H. Meissner, M. Hollerer, M. Kron, S. Schiele, P. Albers, C. Arsov, M. Kuczyk, F. Imkamp, M. Hohenfellner, V. Schütz, J.E. Gschwend, K. Herkommer

Ստացեք ամբողջական տեքստը